6月12日，上海医药（601607/02607）发布公告，近日，公司下属上药国风的罗沙司他胶囊获得国家药监局颁发的《药品注册证书》，批准生产。该药品为口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，适用于慢性肾脏病引起的贫血。药品规格为20mg和50mg，注册分类为化学药品4类。 2026年一季度，上海医药实现收入752.62亿元，归母净利润14.18亿元。（文章来源：财中社）
Source Link6月12日，上海医药（601607/02607）发布公告，近日，公司下属上药国风的罗沙司他胶囊获得国家药监局颁发的《药品注册证书》，批准生产。该药品为口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，适用于慢性肾脏病引起的贫血。药品规格为20mg和50mg，注册分类为化学药品4类。 2026年一季度，上海医药实现收入752.62亿元，归母净利润14.18亿元。（文章来源：财中社）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.